Euroclinic announces the start of its collaboration with Professor of Infectious Diseases Nikos Sypsas, a distinguished scientist with an extensive clinical, research and academic career. Mr Sypsas will head the Internal Medicine Clinic and chair the Hospital Infection Control Committee, while also serving on the Scientific Council on Ethics and Conduct.
His appointment marks a significant step in further strengthening Euroclinic’s medical team and forms part of the hospital’s broader plan to continually improve its healthcare services, with a focus on clinical excellence, patient safety and high-quality care.
Mr Nikos Sypsas is Professor of Pathophysiology and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens and president of the Hellenic Society for Infectious Diseases. He graduated from the Medical School of the National and Kapodistrian University of Athens and holds a PhD from the University of Zurich Medical School. He specialised in infectious diseases at Massachusetts General Hospital and Harvard University in Boston, US. He has many years’ experience in hospital-acquired infections and infections in immunocompromised patients, and has served as head of the Infectious Diseases Unit and chair of the Hospital Infection Control Committee at Laiko Hospital. His expertise and scientific experience strengthen Euroclinic’s ability to respond effectively to complex medical needs with modern, evidence-based treatment approaches.
The prevention and control of hospital-acquired infections are a strategic priority for Euroclinic and an area in which it aims to excel by implementing modern, internationally recognised practices. In this context, the work of the Hospital Infection Control Committee, under Mr Sypsas’s guidance, will focus on systematically monitoring and assessing quality and safety indicators and ensuring the rational use of antimicrobials. At the same time, stronger multidisciplinary collaboration and ongoing training for medical and nursing staff will help embed internationally recognised practices and continually improve clinical care.
Welcoming Mr Sypsas, Hlias Rigas, acting CEO and member of Euroclinic’s board, said: “Euroclinic is now entering a new era, in which we are moving faster and with greater dynamism, making continuous changes and improvements aimed at further enhancing the patient experience and the care we provide. Professor Sypsas’s arrival at Euroclinic is a continuation of our strategy and our conviction that we should not rest on our laurels, but should strive for excellence in everything we set out to do. We welcome Mr Sypsas and wish him every success in our joint effort, for the benefit of the people who need and trust us.”
On taking up his duties, Professor Nikos Sypsas said: “Preventing and controlling hospital-acquired infections is a fundamental prerequisite for safe patient care. At Euroclinic, we will work closely with medical and nursing staff to strengthen prevention practices and systematically monitor their effectiveness. Through this collaboration, our aim is to improve the quality of care every day and protect our patients’ health.”
By bringing in highly regarded specialists with extensive expertise, Euroclinic is steadily evolving its healthcare delivery model, investing in medical knowledge, quality and the patient experience, with the aim of providing care that meets today’s needs and the highest standards of medical science.